Market Overview

Fresenius Medical Care Renal Therapies Group Announces Four Abstracts on Velphoro® Accepted for Presentation at the American Society of Nephrology Kidney Week

Share:

Data Demonstrates Switching Patients to Velphoro Doubled the
Percentage of Patients Achieving Serum Phosphorus Control

Fresenius Medical Care Renal Therapies Group announced today that four
abstracts on Velphoro® (sucroferric oxyhydroxide) have been accepted for
presentation at the American Society of Nephrology (ASN) annual Kidney
Week held Oct. 31-Nov. 5, 2017 in New Orleans.

The abstracts describe the real world outcomes in serum phosphorus
control and a significant reduction in pill burden achieved in
hemodialysis patients who switched to Velphoro as part of their routine
clinical care.

Two abstracts focus on a two-year follow-up of patients and include
sub-analyses based on the patients' previous phosphate binder therapy.
One abstract documents the changes in mineral bone disease markers in
hyperphosphatemic patients who achieved target phosphorus ranges. The
fourth abstract describes the change in nutritional markers among
patients with low serum albumin who switched to Velphoro.

"Real world data demonstrates switching patients to Velphoro doubled the
percentage of patients achieving serum phosphorus control. DOPPS
Practice Monitor highlights up to 35 percent of patients are outside of
their target phosphorus goal at any given time," explained Mark
Costanzo, president, Fresenius Medical Care Renal Therapies Group.

All four abstracts were accepted for poster presentations on Thursday,
Nov. 2. All four are available online on the conference's website: https://www.asn-online.org/education/kidneyweek/2017/program-search-abstract.aspx.

Poster Presentations

1)   "Effectiveness of Sucroferric Oxyhydroxide (SO) in Lowering Serum
Phosphorus (sP) in 4,925 Chronic Hemodialysis (HD) Patients
Prescribed SO as part of routine care."
 
Daniel W. Coyne, Linda H. Ficociello, Vidhya Parameswaran, Norma J.
Ofsthun, Claudy Mullon, Robert J. Kossmann, Stuart M. Sprague
 
Session Title: 1201-PO01 Mineral Disease: Ca/Mg/PO4
 
Poster Board #: TH-PO1031
 
2) "Two Year Follow Up on Chronic Hemodialysis (HD) Patients Prescribed
Sucroferric Oxyhydroxide as Part of Routine Care"
 
Stuart M. Sprague, Vidhya Parameswaran, Linda H. Ficociello, Norma
J. Ofsthun, Claudy Mullon, Robert J. Kossmann, Daniel W. Coyne
 
Session Title: 1201-PO01 Mineral Disease: Ca/Mg/PO4
 
Poster Board #: TH-PO1030
 
3) "Serum Albumin and Serum Phosphorus among Hemodialysis Patients
after Initiating Sucroferric Oxyhydroxide (SO)"
 
Kamyar Kalantar-Zadeh, Linda H. Ficociello, Vidhya Parameswaran,
Hasi Mondal, Nicolaos V. Athienites, Claudy Mullon, Robert J.
Kossmann
 
Session Title: 1201-PO01 Mineral Disease: Ca/Mg/PO4
 
Poster Board #: TH-PO1033
 
4) "Changes in Mineral Bone Disease (MBD) Markers in Hemodialysis (HD)
Patients Switched to Sucroferric Oxyhydroxide (SO)."
 
Sandeep Shori, Vidhya Parameswaran, Linda H. Ficociello, Claudy
Mullon, Robert J. Kossmann
 
Session Title: 1201-PO01 Mineral Disease: Ca/Mg/PO4
 
Poster Board #: TH-PO1032

INDICATION

Velphoro® (sucroferric oxyhydroxide) is a phosphate binder indicated for
the control of serum phosphorus levels in patients with chronic kidney
disease on dialysis.

IMPORTANT SAFETY INFORMATION

  • Velphoro must be administered with meals. Velphoro tablets must be
    chewed and not swallowed whole. To aid with chewing and swallowing,
    the tablets may be crushed.
  • Patients with peritonitis during peritoneal dialysis, significant
    gastric or hepatic disorders, following major gastrointestinal (GI)
    surgery, or with a history of hemochromatosis or other disease with
    iron accumulation have not been included in clinical studies with
    Velphoro. Monitor effect and iron homeostasis in such patients.
  • In a parallel design, fixed-dose study of six weeks duration, the most
    common adverse drug reactions to Velphoro chewable tablets in
    hemodialysis patients included discolored feces (12%) and diarrhea
    (6%).
  • Velphoro can be administered concomitantly with oral calcitriol,
    ciprofloxacin, digoxin, enalapril, furosemide, HMG-CoA reductase
    inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine,
    omeprazole, quinidine and warfarin. Take doxycycline at least one hour
    before Velphoro. Velphoro should not be prescribed with oral
    levothyroxine.

For more information, please see full
Prescribing Information
, contact your Fresenius Medical Care North
America representative or visit www.Velphoro.us/hcp.

About Fresenius Medical Care North America

Fresenius Medical Care North America is the premier health care company
focused on providing the highest quality care to people with renal and
other chronic conditions. Through its industry-leading network of
dialysis facilities, outpatient cardiac and vascular labs, and urgent
care centers, as well as the country's largest practice of hospitalist
and post-acute providers, Fresenius Medical Care North America provides
coordinated health care services at pivotal care points for hundreds of
thousands of chronically ill customers throughout the continent. As the
world's largest fully integrated renal company, it offers specialty
pharmacy and laboratory services, and manufactures and distributes the
most comprehensive line of dialysis equipment, disposable products and
renal pharmaceuticals. For more information, visit the FMCNA website at https://fmcna.com.

*Source: https://www.dopps.org/dpm/,
accessed 10/30/2017

View Comments and Join the Discussion!